NAN-190 hydrobromide
CAS: 115338-32-4
Ref. 3D-QEA33832
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued | ||
500mg | Discontinued |
Product Information
- NAN 190
- 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-, monohydrobromide
- 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-, hydrobromide (1:1)
- 2-[4-[4-(2-Methoxyphenyl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)-dione hydrobromide (1:1)
- 2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-isoindoline-1,3-dione hydrobromide
NAN-190 hydrobromide is an experimental drug that is a 5-HT7 receptor antagonist. It has been shown to inhibit the activity of 5-HT7 receptors in rat and human bladder cancer cells. NAN-190 hydrobromide also inhibits the growth of prostate cancer cells and reduces tumour size in mice. NAN-190 hydrobromide is a potent antagonist at both the 5-HT1A and 5-HT2A receptors, which are associated with anxiety and depression, respectively. This compound has not been tested on humans, but it has caused adverse effects in animals such as decreased locomotor activity and weight loss.